Shares of Fulcrum Therapeutics Inc. (FULC) have lost nearly 19% year-to-date and trade around $9.Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing drugs for patients with genetically defined rare diseases in areas of high unmet medical need.The company is all set to report data from its phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in m...
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.